Sign in
Taking people in South AfricaPhase 2/3

Tests atorvastatin for lung inflammation after tuberculosis treatment

Tests atorvastatin against placebo in adults who finished tuberculosis treatment.

Key facts

Who runs it
University of Cape Town
Where
Observatory, South AfricaSee the site
Trial code
Registry title
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
Status
Recruiting
Phase
Phase 2/3
People taking part
220 people, planned
Started
14 Jul 2020
Expected to end
30 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atorvastatin 40mg
  • Placebo oral tablet
Record updated
23 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 who finished 24 weeks of standard TB treatment and were declared cured by the South African TB program. It tests whether atorvastatin 40 mg lowers lung inflammation after TB treatment.

Age
18 to 65 years, body weight 50 kg (110 lb) to 90 kg (198 lb)
Sex
All sexes
Disease stage
Pulmonary TB treated successfully: sputum culture negative at week 16 and TB treatment completed.
Earlier treatment
Must have completed a 24-week course of standard TB treatment (4RHZE/2RH). Cannot have used lipid lowering drugs in the last three months or any trial drug in the last 3 months.
Biomarker or test result
If HIV-positive: on antiretroviral therapy for at least 12 weeks, HIV viral load suppressed, and CD4 count above 350 cells/µL. Liver, kidney, blood count and creatine kinase tests must be within set limits.

Main reasons for not taking part

  • Drug-resistant TB or TB outside the lungs
  • Pregnant or planning pregnancy in the next 6 months
  • Diabetes
  • Taking lipid lowering drugs or immunosuppressive drugs, or allergic to statins
  • Acute illness or fever above 38.0 degrees centigrade

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Has completed the written informed consent process prior to undergoing any pre-screening or screening evaluations and willing to undergo HIV testing
  • Age 18 to 65 years with body weight from 50 kg to 90 kg
  • Clinical response to TB treatment and sputum culture negative at week 16
  • Completed a 24-week course of standard TB treatment (4RHZE/2RH)
  • Defined as "cured" by the TB Control Program of South Africa; Laboratory parameters within 30 days before enrolment:
  • For HIV-infected participants: receiving antiretroviral therapy for at least 12 weeks and suppressed HIV viral load within 30 days prior to enrolment
  • For HIV-infected participants: CD4 counts above 350 cells/µL within 30 days prior to enrolment
  • AST and ALT <3x upper limit of normal (ULN)
  • Creatinine <2x ULN
  • Hemoglobin >7.0 g/dL
  • Platelet count >50 x109 cells/L
  • Creatinine kinase <2x ULN
  • Able and willing to return to follow-up
  • Willing to have samples, including DNA, stored
  • Willing to consistently practice a highly reliable method of pregnancy prevention

Who cannot take part

  • Participant receiving any type of lipid lowering agent at the time of screening, within three months prior to screening or likely to require any lipid lowering agent in the near future
  • Known allergy or contraindications to the investigational drug or any other statins
  • Evidence of drug-resistant TB
  • Unable to take oral medications
  • Disease complications or concomitant illnesses that may compromise safety or interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g. sarcoidosis, rheumatoid arthritis, connective tissue disorder)
  • Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within the past 2 weeks
  • Use of any investigational drug in the previous 3 months
  • Alcohol and substance abuse which might interfere with medication adherence during the trial
  • Acute illness
  • Diabetes as defined by point of care HbA1c≥6.5, random glucose≥200mg/dL (or 11.1mmol/L), fasting plasma glucose≥126mg/dL (or 7.0mmol/L), or the presence of any anti-diabetic agent (including traditional medicines) as a concomitant medicine
  • Fever (temperature >38.0 degrees centigrade)
  • Extrapulmonary TB, including pleural TB and/or large pleural effusion
  • Pregnant or desiring/trying to become pregnant in the next 6 months
  • Any person for whom the physician feels this study is not appropriate

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in South Africa.

  • General Medicine & Global Health, Cape Heart Institute, Faculty of Health Sciences, University of Cape TownObservatory, South AfricaContact: Sandra Mukasa, MDTaking people

About the trial

What the trial wants to find out

This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.

The 2 groups in the trial

  • Atorvastatin (Arm B)Existing treatment, for comparison

    12 weeks of 40 mg atorvastatin therapy per os daily

    Treatment: Atorvastatin 40mg

  • Placebo (Arm C)Placebo, for comparison

    Identical placebo tablet is taken per os daily

    Treatment: Placebo oral tablet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion in HIV-infected and HIV-uninfected Adults Measured by FDG-PET/CT
Plain-language title
Tests atorvastatin for lung inflammation after tuberculosis treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT04147286, who can take part
Record updated
23 August 2024